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ABSTRACT
Intratumoral heterogeneity (ITH) is a prominent feature of kidney cancer. It is
not known whether it has utility in finding associations between protein expression
and clinical parameters. We used ITH that is detected by immunohistochemistry
(IHC) to aid the association analysis between the loss of SWI/SNF components and
clinical parameters.160 ccRCC tumors (40 per tumor stage) were used to generate
tissue microarray (TMA). Four foci from different regions of each tumor were selected.
IHC was performed against PBRM1, ARID1A, SETD2, SMARCA4, and SMARCA2.
Statistical analyses were performed to correlate biomarker losses with patho-clinical
parameters. Categorical variables were compared between groups using Fisher’s
exact tests. Univariate and multivariable analyses were used to correlate biomarker
changes and patient survivals. Multivariable analyses were performed by constructing
decision trees using the classification and regression trees (CART) methodology. IHC
detected widespread ITH in ccRCC tumors. The statistical analysis of the “Truncal
loss” (root loss) found additional correlations between biomarker losses and tumor
stages than the traditional “Loss in tumor (total)”. Losses of SMARCA4 or SMARCA2
significantly improved prognosis for overall survival (OS). Losses of PBRM1, ARID1A
or SETD2 had the opposite effect. Thus “Truncal Loss” analysis revealed hidden links
between protein losses and patient survival in ccRCC.

INTRODUCTION

Intratumoral Heterogeneity (ITH). ITH was discovered
in many types of cancers including leukemia [2],
glioblastoma [3], colon [4], pancreatic [5], ovarian [6],
breast [7] and clear cell renal cell carcinoma (ccRCC)
cancers [8, 9]. ITH suggest that tumor development occurs
in a branched fashion instead of a linear one.

What is intratumoral heterogeneity (ITH)?
One or a few cancerous cells with a few founding
mutation(s) are the origins of tumors, then during tumor
development additional mutations occurred to aid
progression [1]. Consequently in many cancers different
regions of a tumor share the same founding mutations
but have different mutations that happened later. This
regionally mixed mutational landscape is defined as
www.impactjournals.com/oncotarget

ITH and mutations in ccRCC
In ccRCC the loss of function of von-Hippel Lindau
tumor suppressor (VHL) happens in around 80% of tumors.
37423
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It is inactivated through DNA mutations or promoter
hypermethylation, and it is the founding mutation for
ccRCC [10]. The familial VHL syndrome, which includes
ccRCC as one of the lesions, is caused by germline VHL
mutations. In recent years, large-scale sequencing studies
identified additional mutated tumor suppressors [11–13].
Around 40% of ccRCC tumors were found to harbor
mutations in polybromo-1 (PBRM1), a component of a
SWI/SNF chromatin-remodeling complex [11]. In addition,
10–15% of ccRCC tumors have inactivating mutations in
either BRCA1-associated protein 1 (BAP1) or SET domain
containing 2 (SETD2), a histone deubiquitinase and a
histone methyltransferase respectively [12].
Gerlinger et al discovered that ITH was very
prevalent in ccRCC [9]. They also identified convergent
phenotypic evolution. In the same tumor, distinct
mutations at different parts of the tumor could inactivate
the same tumor suppressor genes such as SETD2,
Phosphatase And Tensin Homolog (PTEN), and Lysine
Demthylase 5C (KDM5C/JARID1C). In their analysis of
eight kidney cancer samples, only chromosome 3p loss
and VHL aberrations were present in all the cases. They
were called truncal losses (root and ubiquitous losses)
[8]. In tumors with PBRM1 mutations, half of them were
truncal [8].

nucleus (Figure 1). This is consistent with the known roles
of these proteins as chromatin regulators.

The summary of protein expression losses in
tumors and foci
To be consistent with rule on DNA mutation calling
in tumors, we decided that if the expression of a marker
was gone in one focus out of four foci from a tumor, then
that tumor had a loss of expression of that marker. The
detailed tally of the protein expression loss was described
before [14]. We found that 31% of tumors lost expression
of PBRM1. In addition, 51% of them lost ARID1A, 14%
of them lost SETD2, 15% of them lost SMARCA4, and
38% of them lost SMARCA2 expressions (Table 2). If the
loss of protein expression was calculated with foci, 17%,
32%, 6.1%, 6.9% and 22% of foci lost the expressions of
PBRM1, ARID1A, SETD2, SMARCA4, and SMARCA2
respectively (Table 2).

The truncal loss analysis revealed hidden links
between biomarker losses and tumor stages
The relationships between different molecular
events can be inferred by clonal ordering [20], and a
phylogenetic tree can be constructed to represent this. If
a molecular event is a founding one, it will be present in
most regions of a tumor. We call it a truncal (early or root)
change. Conversely, if a molecular event arises late during
tumor development, this change might be only detected in
one or two foci. We call it a branch (late) change. Tumor
#7 from the stage 1 group provided an example: the
SMARCA2 loss was a truncal event, PBRM1 loss was a
branch event, while ARID1A and SMARCA4 losses were
branch events that happened even later (Figure 2A).
Next we examined the truncal changes that occurred
in these tumors. Each tumor stage was represented by
40 tumors, and 23, 23, 26, 30 cases from stage 1 to 4 had
protein expression losses respectively (Figure 2B). For
brevity, we called the protein losses A (ARID1A loss), P
(PBRM1 loss), S (SETD2 loss), G (SMARCA4/BRG1
loss), M (SMARCA2/BRM loss). We grouped the protein
losses into three camps: Only Truncal Loss (it includes
tumors with truncal loss that is the only truncal loss),
Truncal Loss (Total) (it includes tumors with truncal loss,
either alone or in combination), or the Loss in Tumor
(Total) (it includes all the tumors with protein losses).
We then used Fisher’s exact tests to examine whether
the biomarker losses were statistically associated with
high tumor stage (stage 4). In the case of PBRM1, the
loss frequencies increased with stage and the associations
between truncal loss groups with high stage had much
smaller p values than that of Loss in Tumor (Total), which
suggested higher confidence (Figure 2C). For SMARCA2,
the loss frequency decreased when stage increased. The
truncal loss groups had very small p values, while that of

Can ITH be examined by IHC? can ITH be
useful in predicting clinical outcome?
The ITH in ccRCC was primarily studied with Next
Gen Sequencing (NGS). It provided high quality data and
great resolution, but it is expensive and labor intensive.
Consequently the number of the analyzed samples is
small which prevented statistical analysis to correlate with
clinical parameters. We investigated whether IHC could
successfully characterize ITH. We further investigated
whether the ITH analysis at a much larger scale could
reveal hidden correlations between the loss of biomarkers
and clinical parameters.

RESULTS
Immunohistochemical analysis of ccRCC foci on
tissue microarray (TMA)
The demographic, pathological and clinical
parameters of the ccRCC patients we selected for this
study are presented in Table 1. We excised four foci from
different areas from each tumor to construct TMA. In our
previous publication we examined the specificity of the
antibodies with cells expressing shRNA against target
proteins and found them to be specific [14]. In addition
many of these antibodies revealed expression losses when
mutations in the target genes were detected [15–19]. With
validated antibodies we stained five sets of the TMA. We
found that all five proteins were stained primarily in the
www.impactjournals.com/oncotarget
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Table 1: Characteristics of ccRCC patients included in this study
Number of patients

160

Age [average (range)]
Gender
Male
Female
Race
African American
Caucasian
Other
Grade
Grade 1
Grade 2
Grade 3
Grade 4
Path T Stage
T1
T2
T3
T4
N Stage
N0
N1 and N2
NX
M Stage
M0
M1
MX
TNM Stage
1
2
3
4
Histology
Clear Cell only

59.7 (23–82)
118
42
9
148
3
11
37
71
40
47
51
60
2
118
13
29
102
37
21
40
40
40
40
160

Loss in Tumor (Total) was a borderline 0.05 (Figure 2C).
For ARID1A, the higher stages had more protein losses,
but just the Only Truncal Loss group had a statistically
significant association with high stage (Figure 2C).
SMARCA4 loss did not show any statistically significant
association with high stage (Figure 2C). As for SETD2,
only the Truncal Loss (Total) group was significantly
associated with high stage (p = 0.032) (Figure 2C).

with patient survival than those of total losses. Cox
proportional hazards (PH) models were utilized to
correlate recurrence-free survival (RFS) with biomarker
losses. For the protein losses, two groups of protein losses
were used for analysis: one included all the truncal losses
(Proteinname.Truncal). The other one included all the
protein losses (Proteinname.Total). In univariate analyses,
SETD2.Total, SMARCA2.Total, SMARCA4.Truncal, and
SMARCA2.Truncal displayed a significant association with
RFS with p values near or below 0.05 while SMARCA4.
Total and SETD2.Truncal showed marginally significant
associations (Table 3). In further multivariable analysis,
only SETD2.Total’s association with RFS remained
statistically significant. The Kaplan-Meier curve showed
that patients that lost SETD2 staining in tumors had shorter

The truncal loss analysis reveals hidden
associations between protein losses and patient
survival
It is not known whether truncal losses of protein
markers would reveal statistically different associations
www.impactjournals.com/oncotarget
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Table 2: Summary of protein expression losses in ccRCC tumors
PBRM1
ARID1A
SETD2
SMARCA4
SMARCA2

Tumors with protein expression loss
31% (49/160)
51% (81/160)
14% (23/160)
15% (24/160)
38% (61/160)

Foci with protein expression loss
17% (108/638)
32% (202/638)
6.1% (39/638)
6.9% (44/638)
22% (143/638)
Truncal, SMARCA2.Truncal and OS showed p values
below or near 0.1 (Table 4). They were used for further
multivariable analysis. With the exception of SMARCA2.
Truncal, all the other biomarker losses showed a
statistically significant association with OS. It was found
that losses of SMARCA4.Truncal or SMARCA2.Total

RFS (Figure 3). Thus, most of the markers do not appear to
be associated with RFS and the ITH analysis did not help.
The overall survival (OS) is clinically crucial and
has greater importance than RFS. In univariate analyses,
tests of association between ARID1A.Total, SETD2.
Total, SMARCA2.Total, PBRM1.Truncal, SMARCA4.

Figure 1: The Immunohistochemical analysis of ARID1A, PBRM1, SMARCA4, SMARCA2, SETD2 in ccRCC
foci. Representative foci stained for different markers showing scores of 2, 1, 0 (left, middle, and right). The staining of stromal and
immunological cells serves as internal positive controls.
www.impactjournals.com/oncotarget
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were associated with significantly better prognosis for
patients (hazard ratio of 2.55 and 3.59 respectively), while
losses of ARID1A.Total, PBRM1.Truncal, or SETD2.Total
were associated with worse prognosis (hazard ratio of
0.23, 0.42, and 0.3 respectively). Truncal loss counts only
the cases with truncal protein expression losses, while the
Total loss includes all the tumors with protein expression
losses. The Kaplan-Meier curves showed the same trends
(Figure 4).
In order to further analyze our data, classification
and regression trees (CART) methodology was applied

to construct decision trees with multivariable analyses.
RFS analysis revealed that patients whose SMARCA2.
Truncal staining was negative (≤ 0) had significantly
longer recurrence free survival than patients with
positive SMARCA2 staining (Figure 5A). OS analysis
revealed that patients whose SMARCA2.Truncal and
PBRM1.Truncal staining were both negative showed
the worst overall survival while those with negative
SMARCA2.Truncal staining and positive PBRM1.
Truncal staining showed the best overall survival
(Figure 5B).

Figure 2: The truncal loss analysis revealed hidden links between protein loss and tumor stages. (A) How a phylogenetic
tree was constructed. A: ARID1A loss; M: SMARCA2 loss; P: PBRM1 loss, G: SMARCA4 loss; S: SETD2 loss. (B) Truncal losses of the
markers at each stage, either alone or in combination, were presented. (C) Fisher’s exact tests were performed to calculate the p values of
the associations between the protein marker losses and stages.
www.impactjournals.com/oncotarget
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Table 3: Univariate and multivariable analyses of indicated biomarker losses and their associations
with recurrence-free survival
Recurrence-free survival
Univariate analysis

All patients (160)
Hazard Ratio (95% CI)

p value

ARID1A.Total
SETD2.Total
SMARCA4.Total
SMARCA2.Total
PBRM1.Truncal
SETD2.Truncal
SMARCA4.Truncal
SMARCA2.Truncal
Multivariable analysis

0.93 (0.59–1.46)
0.754
0.50 (0.28–0.89)
0.017
1.98 (0.98–4.01)
0.056
1.83 (1.12–3.0)
0.015
0.79 (0.55–1.14)
0.210
0.72 (0.51–1.02)
0.065
1.85 (1.06–3.23)
0.031
1.79 (1.31–2.46)
0.0002
All patients (160)
Hazard Ratio (95% CI)
p value
SETD2.Total
0.27 (0.08–0.90)
0.034
SMARCA4.Total
1.63 (0.55–4.82)
0.380
SMARCA2.Total
1.57 (0.74–3.36)
0.244
SETD2.Truncal
1.13 (0.61–2.11)
0.695
SMARCA4.Truncal
1.35 (0.64–2.85)
0.429
SMARCA2.Truncal
1.32 (0.85–2.07)
0.218
The biomarker loss was subjected to multivariable analysis if its p value was below 0.1. CI = confidence interval.

DISCUSSION

Intratumoral heterogeneity is one of the major reasons
that cancers are hard to eradicate. A major trend in cancer
therapies, precision medicine, based upon the notion that
the tumors in each person need a few major driving DNA
mutations for tumorigenesis and tumor maintenance, and
the drugs that hit the vulnerabilities conferred by such
mutations will lead to clinical efficacy. This was proven

The loss of protein expression of important cancer
genes can occur in a branched fashion or linear fashion in
different parts of the same tumor (Figure 6). The branched
fashion occurs in the vast majority of ccRCC tumors,
constituting the intratumoral heterogeneity phenomena.

Figure 3: Kaplan-Meier analysis of recurrent free survival. The survival curves were calculated based on SETD2 staining:
positive (1) and negative (0). Associated log-rank p value was indicated. n: number of cases.
www.impactjournals.com/oncotarget
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Table 4: Univariate and multivariable analyses of indicated biomarker losses and their associations
with overall survival
Overall survival
Univariate analysis
ARID1A.Total
SETD2.Total
SMARCA4.Total
SMARCA2.Total
PBRM1.Truncal
SETD2.Truncal
SMARCA4.Truncal
SMARCA2.Truncal
Multivariable analysis

All patients (160)
Hazard Ratio (95% CI)
0.69 (0.44–1.08)
0.50 (0.29–0.87)
1.55 (0.82–2.94)
1.50 (0.94–2.38)
0.60 (0.42–0.85)
0.77 (0.54–1.09)
1.97 (1.13–3.45)
1.60 (1.18–2.17)
All patients (160)
Hazard Ratio (95% CI)

p value
0.104
0.014
0.182
0.085
0.004
0.139
0.017
0.002
p value

ARID1A.Total
0.23 (0.09–0.55)
0.001
SETD2.Total
0.30 (0.15–0.58)
0.0003
SMARCA2.Total
3.59 (1.62–7.94)
0.002
PBRM1.Truncal
0.42 (0.29–0.63)
2.45e-05
SMARCA4.Truncal
2.55 (1.38–4.71)
0.003
SMARCA2.Truncal
0.99 (0.66–1.48)
0.948
The biomarker loss was subjected to multivariable analysis if its p value was below 0.1. CI = confidence interval.
true in many cases: Gleevec for chronic myeloid leukemia
(CML) [21] and gastrointestinal stromal tumors (GIST)
[22], Gefitinib for non-small cell lung cancer carrying
hyperactive and mutated EGFR [23], and Vemurafenib for
melanoma [24]. These drugs do not kill dividing cells nondiscriminately so they tend to be quite effective with mild
side effects. Unfortunately, in most cases tumors would
develop drug resistance sooner or later. In a certain tumor,
ITH could mean that a small percentage of the cancer
cells do not carry the driving mutations, so over time they
would grow up after treatment. Alternatively, some cancer
cells might also harbor other mutations or epigenetic
changes that render them drug resistant [25].
The cost of DNA sequencing prevented it from
being applied to large-scale analysis of ITH. We show
that IHC analysis can describe ITH at a large scale [14].
With the result we first examined whether ITH is useful
in finding correlations between protein losses and high
tumor stage. For ARID1A and SETD2, the statistically
significant associations between marker losses and tumor
stages would have been missed if truncal loss analysis
were not performed (Figure 2). Thus the ITH analysis is
useful here. However, it is highly likely that many tumorderived mutations in the cancer genes, especially the
point mutations, do not lead to protein expression loss, so
mutational analysis will improve the sensitivity of analysis.
Next we examined the links between marker losses
and recurrence-free survival (RFS). Only SETD2.Total
www.impactjournals.com/oncotarget

showed a statistical meaningful association with RFS,
and the loss of SETD2 led to shorter RFS (Table 3 and
Figure 3). Thus these markers are mostly not very useful
in predicting RFS, and ITH analysis did not help either.
The overall survival (OS) measures how long
the patients survive after diagnosis. After multivariable
analysis, ARID1A.Total, SETD2.Total, SMARCA2.Total,
PBRM1.Truncal and SMARCA4.Truncal all showed
statistically significant association with OS: the losses of
ARID1A, SETD2, and PBRM1 were associated with worse
prognosis for the patients, while the losses of SMARCA4
and SMARCA2 were associated with better prognosis
(Table 4). Interestingly, for PBRM1 and SMARCA4, if the
ITH analysis were not performed, their associations with
the OS would not have been discovered. Thus ITH analysis
also unearthed hidden associations between marker losses
and overall survival.
We also used the CART methodology to perform
multivariable analyses. The results were consistent with
PH model results (Tables 3 and 4). Again, ITH analysis
derived truncal losses were key to derive meaningful
associations between marker losses and patient survivals
in this type of association analysis.
ARID1A is a specificity subunit of the SWI/SNF
chromatin-remodeling complex. Decreased ARID1A
expression was prevalent, and it was statistically
associated with shorter patient survivals [26]. Even though
a very low percentage of ccRCC tumors harbor mutations
37429
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Figure 4: Kaplan-Meier analysis of overall survival. The survival curves were calculated based on biomarker staining: positive (1)
and negative (0). Associated log-rank p values were indicated. n: number of cases analyzed.

Figure 5: CART. The decision trees and the survival curves are calculated based on staining of indicated biomarkers: positive (> 0) and

negative (≤ 0). Associated p value was indicated. n: number of cases analyzed. Truncal changes were derived from ITH analysis. (A) CART
analysis of biomarkers with RFS; (B) CART analysis of biomarkers with OS.
www.impactjournals.com/oncotarget
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in ARID1A, the high rate of ARID1A expression loss
clearly indicates that it plays a critical role in cancer
biology in ccRCC, and a clever way to take advantage
of its loss to treat ccRCC is worth serious efforts to
pursue. Decreased expression of SETD2 was also linked
to unfavorable prognosis for patients with nonmetastatic
ccRCC [27]. Both were consistent with our result.
PBRM1 is another specificity subunit of the SWI/SNF
complex. The contribution of PBRM1 mutations to the
clinical outcome of ccRCC patients has been somewhat
controversial [28–31]. Our analysis strongly suggests that
PBRM1 loss is enriched at higher tumor stages (Figure
2) and is strongly associated with worse overall survival
(Table 4 and Figure 4). SMARCA4 and SMARCA2 are
two mutually exclusive catalytic subunits of the SWI/
SNF complex. Their protein losses in ccRCC were
unknown. We found that SMARCA4 and SMARCA2
had prevalent expression loss in ccRCC tumors (Table 2).
In both multivariable analyses, the SMARCA2 loss was
strongly associated with longer patient overall survival.
In Small Cell Carcinoma of the Ovary, Hypercalcaemic
Type (SCCOHT) and Non-Small Cell Lung Cancer
cell cells, SMARCA4 and SMARCA2 acted as tumor
suppressors [19, 32]. Thus the tumor-promoting functions
of SMARCA4 and SMARCA2 might be unique to
ccRCC. Although the oncogenic pathways activated by

SMARCA4 and SMARCA2 in the absence of PBRM1
or ARID1A are currently unknown, they can and should
be identified in ccRCC cells and tumors with PBRM1 or
ARID1A deficiency. The identification of these oncogenic
pathways will prove useful to rationally design therapeutic
strategies to treat ccRCC tumors with PBRM1 or ARID1A
deficiency.

MATERIALS AND METHODS
Sample preparation and TMA preparation
A protocol approved by Fox Chase Cancer Center
IACUC committee (IRB#13-810) was used to obtain
written informed patient consent. Institutional guidelines
and protocols were strictly followed when all samples
were collected.
160 Patients diagnosed with clear cell renal cell
carcinoma with available archived Paraffin fixed tissue
were identified from Fox Chase cancer Center kidney
database. 40 cases from each of the four tumor stages
(Stage I–IV) were randomly picked. A pathologist
reviewed all cases. From each tumor, four different areas
were selected to cover the intratumoral heterogeneity.
Eight tissue microarray blocks (TMA) were built at Fox
Chase Cancer Center biorepository facility.

Figure 6: Branched or linear fashions of protein losses in ccRCC tumors. The branched fashion of protein losses can have two
roots (tumors 1, 3) or one root (tumors 2, 4), but at different parts of the same tumor the protein losses were not uniform, and some protein
losses were only present in a subset of tumor foci. In the case of linear fashion of protein loss, one or multiple proteins were lost at once in
one or multiple foci of the tumors (tumors 5, 6).
www.impactjournals.com/oncotarget
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Immunohistochemistry and scoring

towards variables with many possible splits or missing
values. It utilizes significance testing procedures and results
in unbiased selection among variables measured at different
scales. All tests were two-sided and used a Type I Error of
5% to determine statistical significance. Computations were
performed in the R statistical language and environment
using packages survival and party [36].

The Ventana Discovery ULTRA staining platform
with Discovery CCI (Ventana cat#950-500) was used for
antigen retrieval. The total application time was 64 minutes.
Primary immunostaining step utilized antibodies against
PBRM1 1:50, ARID1A 1:250, SMARCA2 1:50,
SMARCA4 1:200, SEDT2 1:100 in Ventana Antibody
Dilution Buffer (Ventana cat #ADB250). The slides
were incubated for 44 minutes at room temperature.
Secondary immunostaining was done with a rabbit
Horseradish Peroxidase (HRP) multimer cocktail (Ventana
cat#760-500). The immune complexes were developed
with the ultraView Universal DAB (diaminobenzidine
tetrahydrochloride) Detection Kit (Ventana cat#760-500).
After this the slides were washed with a Tris based reaction
buffer (Ventana cat#950-300) and stained for 8 minutes with
Hematoxylin II (Ventana cat #790-2208). The antibodies
used for IHC are: PBRM1 (Bethyl labs, Cat# A301-591A),
ARID1A (Sigma-Aldrich, Cat# HPA005456), SMARCA2
(Sigma-Aldrich, Cat# HPA029981), SMARCA4 (Abcam,
Cat# ab110641), SETD2 (ProSci, Cat# 30-305).
Two pathologists (W.J., T.P.) performed the scoring
of the stained foci independently. A score of 2 is given if
greater than 50% of tumor cells were considered positive in
a focus, 1 if less than 50% but greater than 5% of tumor cells
were deemed positive, and 0 if less than 5% of tumor cells
were positive. In the cases where the two pathologists gave
different scores, they examined the foci together to reach a
consensus. If one marker is scored as 0 in one focus, then that
whole tumor is deemed to have a score of 0 for that marker.

Abbreviations
Intratumoral heterogeneity (ITH); Immuno
histochemistry (IHC); Tissue microarray (TMA); Clear cell
Renal Cell Carcinoma (ccRCC); Phosphatase And Tensin
Homolog (PTEN); Lysine Demethylase 5C (KDM5C/
JARID1C); Polybromo-1 (PBRM1); BRCA1-associated
protein 1 (BAP1); SET domain containing 2 (SETD2);
AT-Rich Interaction Domain 1A (ARID1A); SWI/SNF
Related, Matrix Associated, Actin Dependent Regulator Of
Chromatin, Subfamily A, Member 4 (SMARCA4/BRG1);
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(SMARCA2/BRM); Classification and regression trees
(CART); von-Hippel Lindau tumor suppressor (VHL);
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Statistical analysis
Categorical variables were compared between groups
using Fisher’s exact tests. Univariate and multivariable Cox
proportional hazards (PH) models were used to associate
overall survival (OS) and recurrence-free survival (RFS) with
grade, stage and biomarkers of interest. The markers included
Arid1A.Total, SetD2.Total, SMARCA4.Total, SMARCA2.
Total, PBRM1.Truncal, SetD2.Truncal, SMARCA4.Truncal
and SMARCA2.Truncal. Estimates of hazard ratio (HR)
including 95% confidence intervals were computed for
each variable. Goodness-of-fit of the Cox PH model was
assessed using Schoenfeld residuals [33]. For variables
showing a time-varying effect on survival, weighted Cox
regression methods were used to account for these effects
by computing average HRs [34]. In addition, multivariable
analyses were performed by constructing decision trees using
the classification and regression trees (CART) methodology.
A decision tree is a logical model represented as a binary
tree that shows how the value of a response variable such
as OS or RFS can be predicted by using the values of a set
of clinical variables and biomarkers. The unified CART
framework that embeds recursive binary partitioning into
the theory of permutation tests was used [35]. This approach
overcomes the problem of over-fitting and selection bias
www.impactjournals.com/oncotarget
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